Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0043-116851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Treatment of severe flares in Crohn's disease and ulcerative colitis].
Inn Med (Heidelb)
January 2025
Abteilung für interventionelle gastroenterologische Endoskopie, Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Essen, Essen, Deutschland.
Background: In chronic inflammatory bowel diseases (IBD), severe flares are characterized by intense inflammatory activity and a high disease burden for patients. Treatment addresses both short-term goals (e.g.
View Article and Find Full Text PDF[Efficient treatment of mild Crohn's disease and mild ulcerative colitis].
Inn Med (Heidelb)
December 2024
Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz.
The cornerstone of treatment for mild ulcerative colitis is still the oral or topical (rectal) application of aminosalicylates (5-ASA). 5‑ASA preparations are often only administered orally in mild ulcerative colitis. Study data show that in ulcerative proctitis and left-sided colitis, rectal 5‑ASA preparations are even more effective than oral administration.
View Article and Find Full Text PDFEffect of Bacteroides on Crohn's disease.
Z Gastroenterol
November 2024
Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou University, Yangzhou, China.
Crohn's disease (CD), also known as cicatrizing enteritis, is an inflammatory bowel disease that occurs in the distal ileum and right colon of unknown cause and is also called inflammatory bowel disease (IBD) with ulcerative colitis (UC). In recent years, intestinal biota have been confirmed to play a significant role in various gastrointestinal diseases. Studies have found that intestinal microbiota disorders are closely associated with the onset and progression of Crohn's disease.
View Article and Find Full Text PDFLeveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.
Adv Healthc Mater
November 2024
Institute of Biochemistry II, Center for Sepsis Control and Care, Jena University Hospital, 07747, Jena, Germany.
Inflammatory bowel disease (IBD) is an idiopathic gastrointestinal disease with drastically increasing incidence rates. Due to its multifactorial etiology, a precise investigation of the pathogenesis is extremely difficult. Although reductionist cell culture models and more complex disease models in animals have clarified the understanding of individual disease mechanisms and contributing factors of IBD in the past, it remains challenging to bridge research and clinical practice.
View Article and Find Full Text PDF[Lysosomal storage disorders - Fabry disease and Gaucher disease].
Dtsch Med Wochenschr
October 2024
Article Synopsis
- - Lysosomal storage disorders (LSD) are genetic metabolic conditions caused by issues with lysosomes, affecting roughly 1 in 5000 births, with Fabry and Gaucher diseases being the most prevalent
- - These disorders primarily result from enzyme deficiencies, leading to the buildup of undegraded materials in cells, which can disrupt normal cellular function and cause toxicity or inflammation
- - There are approved treatment options for Fabry and Gaucher diseases, including enzyme replacement therapy, chaperone therapy, and substrate reduction therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!